Our attorneys counter this by presenting evidence of side effects reported after the drug was approved, drawing on evidence from the FDA safety communications and expert testimony
While many symptoms improve over time, GI discomfort remains a leading reason for discontinuation, reinforcing the need for gradual dose titration, patient education, and a personalized approach when choosing a GLP-1 therapy
Y.ZhaoL.NiuX
[D 4 ]-Hypotaurine (m/z 114 m/z 96
Dual Incretin Signaling# GLP-1R activation : Enhances glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, reduces appetite via hypothalamic signaling GIPR activation : Potentiates insulin secretion, may improve lipid metabolism and fat distribution, enhances central appetite regulation Synergistic effects : The combination produces greater glycemic and weight effects than either pathway alone Pharmacokinetics# The C20 fatty diacid modification enables albumin binding, yielding a half-life of approximately 5 days and supporting once-weekly administration
